高危去势抵抗性前列腺癌中雄激素受体剪接变异体7与激素治疗耐药的前瞻性多中心验证:PROPHECY研究
PROPHECY是一项多中心前瞻性盲法研究,纳入118例开始接受阿比特龙醋酸酯或恩扎卢胺治疗的高危转移性去势抵抗性前列腺癌(mCRPC)男性,验证基线循环肿瘤细胞(CTC)AR-V7对影像学或临床无进展生存期(PFS)的预后意义。Johns Hopkins和Epic两种AR-V7检测均独立与更短PFS和总生存期(OS)相关,AR-V7阳性者确认的前列腺特异性抗原缓解率(0%至11%)或软组织缓解率(0%至6%)更低。
要点
- 两种CTC AR-V7检测均独立与更短PFS和OS相关。
- AR-V7阳性mCRPC患者确认的PSA缓解率为0%至11%,软组织缓解率为0%至6%。
- 两种AR-V7检测之间观察到的百分比一致率为82%。
核心结论
- 通过两种血液检测在CTC中检测到AR-V7,与接受阿比特龙或恩扎卢胺治疗者更短的PFS和OS独立相关,此类mCRPC男性应接受替代治疗。
研究设计与样本
- PROPHECY(ClinicalTrials.gov标识符:NCT02269982)是一项多中心、前瞻性盲法研究,纳入118例开始接受阿比特龙醋酸酯或恩扎卢胺治疗的高危mCRPC男性。
- 主要目标为采用Johns Hopkins大学改良AdnaTest CTC AR-V7 mRNA检测和Epic Sciences CTC核特异性AR-V7蛋白检测,基于影像学或临床无进展生存期(PFS)验证基线CTC AR-V7的预后意义。
- 总生存期(OS)和前列腺特异性抗原缓解为次要终点。
主要发现
- Johns Hopkins和Epic AR-V7检测均独立与更短PFS相关(风险比分别为1.9 [95%CI 1.1至3.3;P=0.032]和2.4 [95%CI 1.1至5.1;P=0.020])。
- 校正CTC数量和临床预后因素后,两种检测均独立与更短OS相关(风险比分别为4.2 [95%CI 2.1至8.5]和3.5 [95%CI 1.6至8.1])。
- AR-V7阳性mCRPC男性确认的前列腺特异性抗原缓解较少(0%至11%)或软组织缓解较少(0%至6%)。
- 两种AR-V7检测之间观察到的百分比一致率为82%。
临床怎么用
- 作者认为,通过两种血液检测在CTC中检测到AR-V7与接受阿比特龙或恩扎卢胺治疗者更短PFS和OS独立相关,此类mCRPC男性应接受替代治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given that previous reports suggested that circulating tumor cell (CTC) AR-V7 detection is a poor prognostic indicator for the clinical efficacy of secondary hormone therapies, we conducted a prospective multicenter validation study. PATIENTS AND METHODS: PROPHECY ( ClinicalTrials.gov identifier: NCT02269982) is a multicenter, prospective-blinded study of men with high-risk mCRPC starting abiraterone acetate or enzalutamide treatment. The primary objective was to validate the prognostic significance of baseline CTC AR-V7 on the basis of radiographic or clinical progression free-survival (PFS) by using the Johns Hopkins University modified-AdnaTest CTC AR-V7 mRNA assay and the Epic Sciences CTC nuclear-specific AR-V7 protein assay. Overall survival (OS) and prostate-specific antigen responses were secondary end points. RESULTS: We enrolled 118 men with mCRPC who were starting abiraterone or enzalutamide treatment. AR-V7 detection by both the Johns Hopkins and Epic AR-V7 assays was independently associated with shorter PFS (hazard ratio, 1.9 [95% CI, 1.1 to 3.3; P = .032] and 2.4 [95% CI, 1.1 to 5.1; P = .020], respectively) and OS (hazard ratio, 4.2 [95% CI, 2.1 to 8.5] and 3.5 [95% CI, 1.6 to 8.1], respectively) after adjusting for CTC number and clinical prognostic factors. Men with AR-V7-positive mCRPC had fewer confirmed prostate-specific antigen responses (0% to 11%) or soft tissue responses (0% to 6%). The observed percentage agreement between the two AR-V7 assays was 82%. CONCLUSION: Detection of AR-V7 in CTCs by two blood-based assays is independently associated with shorter PFS and OS with abiraterone or enzalutamide, and such men with mCRPC should be offered alternative treatments.
引用
- Armstrong AJ, Halabi S, Luo J, et al. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol. 2019. PMID: 30865549. doi:10.1200/JCO.18.01731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。